|
Jul 1
|
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
|
|
May 20
|
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
|
|
Mar 16
|
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week
|
|
Mar 11
|
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
|
|
Mar 11
|
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
|
|
Mar 10
|
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
|
|
Feb 20
|
Why Trevi Therapeutics (TRVI) Is Advancing Today
|
|
Oct 3
|
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
|
|
Sep 30
|
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
|
|
Jun 27
|
Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation
|
|
May 13
|
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Trevi Therapeutics to Participate in Upcoming Conferences
|
|
May 8
|
Q1 2024 Trevi Therapeutics Inc Earnings Call
|
|
May 7
|
Trevi Therapeutics Reports Q1 2024 Financial Results: A Detailed Analysis
|
|
May 7
|
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
|
|
May 1
|
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
|
|
Apr 18
|
Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|
|
Apr 9
|
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
|
|
Apr 4
|
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
|
|
Apr 4
|
Trevi Therapeutics to Participate in Upcoming April Events
|